TargetedTherapies ?

Announcing the investigator initiated trial Pembro IST is anticipated to expand enrollment to UCLA satellite sites.

Pembrolizumab is an antibody that inhibits the PD-1/PD-L1 immune checkpoint and allows the immune system to destroy cancer cells. Pembro IST is a study of pembrolizumab in patients with non-small cell lung cancer whose tumors tested positive for the protein PD-L1 (≥1%) using an approved test and have an EGFR mutation.

Read the UCLA Thoracic Oncology February, 2017 Patient Newsletter here: Issue 50 Feb TOTR Patient Newsletter